Abstract Background and Aim Genotype 3b hepatitis C virus (HCV) infection represents
approximately 50% of patients with genotype 3 in China. We compared the efficacy of …

The fixed-dose combination of sofosbuvir, a nucleotide analogue NS5B polymerase
inhibitor, and velpatasvir, a second-generation NS5A inhibitor, has been approved by the …

Summary Background Hepatitis C virus (HCV) genotype 4 is the predominant type of HCV
found in sub-Saharan Africa. Various genotype 4 subtypes, such as 4r, frequently have …

Hepatitis C virus (HCV), a member of the Flaviviridae family, affects approximately 3% of the
world's population and is becoming the leading cause of liver disease in the world …

This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: Effective, pangenotypic treatments for hepatitis C virus (HCV) …

Background The all-oral combination of daclatasvir 60mg QD, a first-in-class HCV NS5A
inhibitor with pan-genotypic activity in vitro, and asunaprevir 1 00mg BID, a selective NS3 …

Purpose The pharmacology, pharmacokinetics, interaction potential, efficacy, and safety of
the newest direct-acting antiviral (DAA) medication for the treatment of chronic hepatitis C …

Given the global importance of chronic hepatitis C virus infection as a major health burden,
there is still a need for treatment options that are more efficient, safer, simpler, more …

Chronic hepatitis C virus (HCV) infection is a main health problem in Egypt causing high
rates of mortalities. Egypt has the highest HCV prevalence in the world, with specific HCV …

Background Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for
whom treatment with peginterferon is not an option, or who have not had a response to prior …